StreetInsider.com News Articles

Piper Sandler on TransMedics Group (TMDX): 'Assessing the $2.2B U.S. Kidney Opportunity'

Wed, 22 Jul 2026 09:26:54 -0400

Piper Sandler analyst Matt O'Brien reiterated an Overweight rating and $120.00 price target on TransMedics Group (NASDAQ: TMDX).

The analyst commented: "Assessing the $2.2B U.S. Kidney Opportunity; With TransMedics expected to submit its IDE for kidney in early 2027, we dig into the unmet need, clinical data, and market opportunity. Normothermic machine perfusion (NMP) has the opportunity to displace standard of care (hypothermic MP) by enabling real-time assessment and improving transplant logistics that should lower the very high non-use rates and expand the donor pool. There are questions about its ability to improve DGF, pricing, the reimbursement landscape, and market share

TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026

Tue, 21 Jul 2026 16:05:00 -0400

ANDOVER, Mass., July 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2026 after market close on Tuesday, August 4, 2026. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.

TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026

Tue, 21 Jul 2026 16:05:00 -0400

TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026

Tue, 21 Jul 2026 16:05:00 -0400

TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026

Tue, 21 Jul 2026 16:05:00 -0400

Form 4 TransMedics Group, Inc. For: Jul 10 Filed by: Corcoran Nicholas

Tue, 14 Jul 2026 21:38:00 -0400

si-local-file:///var/storage/secattach/20260714/26769479.html

Form 4 TransMedics Group, Inc. For: Jul 10 Filed by: Corcoran Nicholas

Tue, 14 Jul 2026 21:38:00 -0400

si-local-file:///var/storage/secattach/20260714/26769479.html

Form 4 TransMedics Group, Inc. For: Jul 10 Filed by: Hernandez Gerardo

Tue, 14 Jul 2026 21:34:00 -0400

si-local-file:///var/storage/secattach/20260714/26769477.html

Form 4 TransMedics Group, Inc. For: Jul 10 Filed by: Hernandez Gerardo

Tue, 14 Jul 2026 21:34:00 -0400

si-local-file:///var/storage/secattach/20260714/26769477.html

Form 4 TransMedics Group, Inc. For: Jul 10 Filed by: Hassanein Waleed H

Tue, 14 Jul 2026 21:28:00 -0400

si-local-file:///var/storage/secattach/20260714/26769473.html

Form 4 TransMedics Group, Inc. For: Jul 10 Filed by: Hassanein Waleed H

Tue, 14 Jul 2026 21:28:00 -0400

si-local-file:///var/storage/secattach/20260714/26769473.html

TransMedics Group (TMDX) PT Lowered to $120 at Baird

Tue, 14 Jul 2026 06:25:47 -0400

Baird analyst David Rescott lowered the price target on TransMedics Group (NASDAQ: TMDX) to $120.00 (from $140.00) while maintaining a Outperform rating.

TransMedics invests in German aviation firm to expand Europe organ transport

Mon, 06 Jul 2026 07:05:11 -0400

TransMedics Group, Inc. (Nasdaq: TMDX) has completed a strategic investment in PAD Aviation service GmbH, a Germany-based private aviation operator, according to a press release issued July 6, 2026.

The investment is intended to support TransMedics' plans to build a pan-European air and ground logistics network for organ transplant operations, modeled on its existing U.S. National OCS Program.

Founded in 2006 and headquartered in Paderborn, Germany, PAD Aviation operates a fleet of nine Embraer Phenom 300 aircraft and employs more than 40 pilots. The company holds a valid EASA Air Operator Certificate and runs a 24/7 aviation hub focused on time-critical missions,

TransMedics invests in German aviation firm to expand Europe organ transport

Mon, 06 Jul 2026 07:05:11 -0400

TransMedics Group, Inc. (Nasdaq: TMDX) has completed a strategic investment in PAD Aviation service GmbH, a Germany-based private aviation operator, according to a press release issued July 6, 2026.

The investment is intended to support TransMedics' plans to build a pan-European air and ground logistics network for organ transplant operations, modeled on its existing U.S. National OCS Program.

TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH

Mon, 06 Jul 2026 07:05:00 -0400

Strategic investment in Germany-based PAD Aviation, a premier European private aviation operator, lays the foundation for TransMedics to establish a dedicated organ transplantation air logistics network across Europe

ANDOVER, Mass., July 6, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the closing of its strategic investment in PAD Aviation, a premier Germany-based private aviation operator.

TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH

Mon, 06 Jul 2026 07:05:00 -0400

TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH

Mon, 06 Jul 2026 07:05:00 -0400

TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH

Mon, 06 Jul 2026 07:05:00 -0400

William Blair on TransMedics Group (TMDX): 'We believe TransMedics’ second-quarter sales will exceed consensus estimates'

Wed, 01 Jul 2026 11:41:02 -0400

William Blair analyst Ryan Daniels reiterated an Outperform rating and {REMOVEPT} price target on TransMedics Group (NASDAQ: TMDX).

The analyst comments "We believe TransMedics’ second-quarter sales will exceed consensus estimates, based on our final analysis of second-quarter industry- and company-specific data points. More specific, based on our analysis of flight volume trends in the period (detailed below), we believe second-quarter revenue could approximate $189 million, versus the current Street estimate of $184.7 million. Our analysis is further supported by weekly organ transplant activity throughout the second quarter (also detailed below). TransMedics shares have fallen approximately 30% after reporting first-quarter results, due

TD Cowen on TransMedics Amid 6% Gain: 'transplant logistics business experienced ~18.5% y/y growth'

Wed, 01 Jul 2026 10:34:08 -0400

TD Cowen analyst Joshua Jennings reiterated a Buy rating and $120.00 price target on TransMedics Group (NASDAQ: TMDX), according to a press release statement.

Jennings cited tracking data on U.S. heart, liver, and lung transplant volumes alongside TransMedics Aviation flight activity. U.S. transplant volumes for the first 13 weeks of the second quarter of 2026 showed 5% year-over-year growth across all three indications — liver, heart, and lung — representing a sequential acceleration from 4% growth recorded in the first quarter of 2026.

Flight tracking data indicated approximately 18.5% year-over-year growth and approximately 11.5% sequential growth in TransMedics Aviation flight volumes during

TD Cowen on TransMedics Amid 6% Gain: 'transplant logistics business experienced ~18.5% y/y growth'

Wed, 01 Jul 2026 10:34:08 -0400

TD Cowen analyst Joshua Jennings reiterated a Buy rating and $120.00 price target on TransMedics Group (NASDAQ: TMDX), according to a press release statement.

Flight tracking data indicated approximately 18.5% year-over-year growth and approximately 11.5% sequential growth in TransMedics Aviation flight volumes during

TransMedics Group (TMDX) Reiterated at Hold by Stifel Post ATC Meeting

Fri, 26 Jun 2026 07:53:16 -0400

Stifel analyst Thomas Stephan reiterated a Hold rating and $80.00 price target on TransMedics Group (NASDAQ: TMDX).

The analyst commented, "This week, we attended American Transplant Congress (ATC), which included a TMDX management meeting and conversations with four abdominal transplant surgeons. Following our TMDX management meeting, we feel our prior flight data-driven forecast for 2Q26 revenue of $195M (above Street) may be aggressive, with management pointing to increased dry-runs. Current consensus seemingly is a more comfortable spot. Additionally, Street’s 2026/2027 EPS estimates may have further downside potential. Based on these near-term dynamics, we now view TMDX as more own-able after 2Q26

TransMedics Group (TMDX) PT Raised to $80 at Stifel on Q2 Top-line Beat

Thu, 18 Jun 2026 07:06:03 -0400

Stifel analyst Thomas Stephan raised the price target on TransMedics Group (NASDAQ: TMDX) to $80.00 (from $75.00) while maintaining a Hold rating.

The analyst commented, "Strengthening flight data points to a solid 2Q26 top-line beat ($195M versus Street’s $183M), in our view—however, the rebound in TMDX trends seemingly is market-driven as donor growth and US transplant volumes were strong in May.As a result, the 2Q26 implied rate of TMDX's share gains remains relatively subdued compared to recent history. Our 2026 market growth and share analysis only implies moderate upside to the revenue guidance midpoint, and we have a downward bias in

TransMedics Group (TMDX) PT Raised to $80 at Stifel on Q2 Top-line Beat

Thu, 18 Jun 2026 07:06:03 -0400

Stifel analyst Thomas Stephan raised the price target on TransMedics Group (NASDAQ: TMDX) to $80.00 (from $75.00) while maintaining a Hold rating.

Form 4 TransMedics Group, Inc. For: Jun 15 Filed by: Gunderson Thomas J.

Wed, 17 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260617/26660086.html